[go: up one dir, main page]

MX2018010683A - Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos. - Google Patents

Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.

Info

Publication number
MX2018010683A
MX2018010683A MX2018010683A MX2018010683A MX2018010683A MX 2018010683 A MX2018010683 A MX 2018010683A MX 2018010683 A MX2018010683 A MX 2018010683A MX 2018010683 A MX2018010683 A MX 2018010683A MX 2018010683 A MX2018010683 A MX 2018010683A
Authority
MX
Mexico
Prior art keywords
galectine
seleno
prevention
treatment
diseases associated
Prior art date
Application number
MX2018010683A
Other languages
English (en)
Other versions
MX394409B (es
Inventor
G Traber Peter
Zomer Eliezer
Shechter Sharon
Nir Raphael
M Johnson Joseph
George Ryan
Original Assignee
Galectin Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences Llc filed Critical Galectin Sciences Llc
Publication of MX2018010683A publication Critical patent/MX2018010683A/es
Publication of MX394409B publication Critical patent/MX394409B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los aspectos de la invención se relacionan con novedosos compuestos sintéticos que tienen una afinidad de enlace con las proteínas de galectina.
MX2018010683A 2016-03-04 2017-03-03 Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos. MX394409B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662303872P 2016-03-04 2016-03-04
PCT/US2017/020658 WO2017152048A1 (en) 2016-03-04 2017-03-03 Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof

Publications (2)

Publication Number Publication Date
MX2018010683A true MX2018010683A (es) 2019-05-27
MX394409B MX394409B (es) 2025-03-24

Family

ID=59744474

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010683A MX394409B (es) 2016-03-04 2017-03-03 Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.

Country Status (11)

Country Link
US (2) US20190367552A1 (es)
EP (1) EP3423461A4 (es)
JP (1) JP7086008B2 (es)
KR (1) KR102346913B1 (es)
CN (1) CN109071585B (es)
AU (1) AU2017228365B2 (es)
CA (1) CA3016343C (es)
IL (2) IL261431B (es)
MX (1) MX394409B (es)
WO (1) WO2017152048A1 (es)
ZA (1) ZA201805900B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209255A1 (en) * 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
AU2018361991A1 (en) * 2017-10-31 2020-05-14 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
CN116063505B (zh) * 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
EP4010076B1 (en) * 2019-08-09 2024-01-17 Idorsia Pharmaceuticals Ltd (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives
CN113476442A (zh) * 2021-07-28 2021-10-08 上海交通大学医学院附属第九人民医院 化合物gb-0139在治疗心肌梗死后心肌过度纤维化的药物中的应用
WO2023195798A1 (ko) 2022-04-06 2023-10-12 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 폐섬유증 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
WO2008060617A2 (en) 2006-11-15 2008-05-22 The Brigham And Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
CN102439021B (zh) * 2009-04-28 2015-09-02 格莱克特生物技术公司 半乳凝素的新型半乳糖苷抑制剂
CA2794066C (en) * 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
AU2012308491B2 (en) * 2011-09-16 2016-01-07 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
AU2012363033B2 (en) 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
EP2620443A1 (en) * 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
IN2015DN02573A (es) * 2012-10-31 2015-09-11 Galecto Biotech Ab
CN104955471A (zh) 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
KR20160122855A (ko) * 2014-03-10 2016-10-24 라 졸라 파마슈티칼 컴파니 신장 질환 치료용 조성물 및 치료방법
US20170095496A1 (en) 2014-04-08 2017-04-06 Galecto Biotech Ab Galactoside inhibitors for new uses

Also Published As

Publication number Publication date
KR20180128419A (ko) 2018-12-03
JP7086008B2 (ja) 2022-06-17
EP3423461A4 (en) 2020-03-25
AU2017228365B2 (en) 2021-05-27
EP3423461A1 (en) 2019-01-09
MX394409B (es) 2025-03-24
IL261431A (en) 2018-10-31
US20230127345A1 (en) 2023-04-27
IL281585B (en) 2022-04-01
IL281585A (en) 2021-05-31
JP2019507194A (ja) 2019-03-14
WO2017152048A1 (en) 2017-09-08
AU2017228365A1 (en) 2018-09-27
CA3016343C (en) 2024-03-26
US20190367552A1 (en) 2019-12-05
ZA201805900B (en) 2019-07-31
IL261431B (en) 2021-04-29
CA3016343A1 (en) 2017-09-08
BR112018067693A2 (pt) 2019-01-08
KR102346913B1 (ko) 2022-01-04
CN109071585A (zh) 2018-12-21
CN109071585B (zh) 2022-08-16

Similar Documents

Publication Publication Date Title
MX392945B (es) Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.
MX2022005211A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
FI3601297T3 (fi) Mcl-1-proteiinia estäviä yhdisteitä
IL282998A (en) Pyridazinone compounds and uses thereof
PT3661514T (pt) Mavacamten para utilização no tratamento da cardiomiopatia hipertrófica
MX2018010683A (es) Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
CO2019013265A2 (es) Anticuerpos que reconocen tau
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
EP3789345A4 (en) COMPOSITE COMPOSITION
IL278122B1 (en) Pteridinone compounds and uses thereof
EP3853332C0 (en) COMPOSITION
EA201891299A1 (ru) Терапевтические антитела к cd9
EP3975919C0 (en) SWEEPABLE HEALING COMPONENTS
EP3882323A4 (en) COMPOSITION
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
DK3840596T3 (da) Sammensætning
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
PE20170287A1 (es) Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
EP3897866C0 (en) ANTIMICROBIAL COMPOSITION
BR112019006844A2 (pt) prevenção de alergia
EP3528810A4 (en) BROMDOMAIN INHIBITOR
MX375918B (es) Composiciones para el tratamiento de la fibrosis y afecciones relacionadas con la fibrosis.
EP3900790A4 (en) COMPOSITION
DK3623432T3 (da) Sammensætning
EP3623430C0 (en) COMPOSITION